Have you been diagnosed with urothelial carcinoma? If so, you may be able to take part in a research study evaluation of an investigational treatment called FX-909 in cancer patients.

Have you been diagnosed with high-risk, relapsed or relapsed/refractory Multiple Myeloma and have already received 1-3 different types of therapy? If so, you may be eligible for our phase 2 study of Selinexor, Daratumumab, Carfilzomib and Dexamethasone.

Have you been diagnosed with Liver cancer. If so, you may be able to take part in a research study looking to to measure the efficacy and safety of durvalumab IV solution plus bevacizumab IV solution after transarterial radioembolization(Y90 glass microsphere TARE) in participants with unresectable HCC amenable to locoregional therapy

Do you have early-stage lung cancer? Were you unable to have surgery or didn't want surgery? If so, you may be able to take part in a clinical trial to find out if adding atezolizumab to radiation is more effective at treating this type of lung cancer.

Do you have triple negative breast cancer? Have you had surgery following chemotherapy? You may be able to participate in a study to find out if stopping pembrolizumab infusions after surgery is just as effective at reducing your risk of cancer recurrence.

Are you between the ages of 40 and 75? Are you willing to give a one-time blood sample? If so, you may be able to take part in a research study that is being used to develop and validate blood tests for early cancer detection.

Are you over 60 and were recently diagnosed with mantle cell lymphoma? You may be able to participate in a research study to determine whether patients who reach complete disease remission after treatment with rituximab and zanubrutinib, will remain longer in remission with or without continuous zanubrutinib treatment.

Do you have untreated Acute Lymphoblastic Leukemia (ALL) and/or you have relapsed or refractory ALL? You may be able to take part in a research study to help us learn more about the effects of a combination of two drugs on your leukemia.

Have you been diagnosed with Glioblastoma? If so, you may be able to take part in a research study looking at the safety of giving a new drug called IGV-001 to patients with Glioblastoma.

Have you been diagnosed with unfavorable risk prostate cancer? Are you looking for treatment options? If so, you may be able to participate in a clinical trial examining different treatment options for prostate cancer.